A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
12/2002
12/13/2002	CA2412876A1 Ceramide kinase and dna encoding the same
12/12/2002	WO2002099115A2 Nucleic acid-associated proteins
12/12/2002	WO2002099113A1 Macrolide compounds, antifungal agents using the same, macrolide compound-producing bacterium belonging to the genus sorangium and process for producing macrolide compounds using the same
12/12/2002	WO2002099108A2 Atp-binding cassette transporter-like molecules and uses thereof
12/12/2002	WO2002099101A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
12/12/2002	WO2002098921A1 Recombinant antibodies against infectious bursal disease virus (ibdv)
12/12/2002	WO2002098901A2 Peptide deformylase inhibitors
12/12/2002	WO2002098882A1 Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture
12/12/2002	WO2002098880A1 5-ethyl-imidazotriazinones
12/12/2002	WO2002098876A1 Cak inhibitors and uses thereof
12/12/2002	WO2002098873A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	WO2002098482A2 System for osmotic delivery of pharmaceutically active agents
12/12/2002	WO2002098463A1 Antifungal compositions
12/12/2002	WO2002098443A2 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
12/12/2002	WO2002098430A1 Antimycotic agent
12/12/2002	WO2002098424A1 Novel anti-infectives
12/12/2002	WO2002098422A1 Use of methylnaltrexone to treat immune suppression
12/12/2002	WO2002098402A1 Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
12/12/2002	WO2002098401A1 Medicinal composition containing mucin
12/12/2002	WO2002098398A1 Methods for preventing and treating diseases and conditions associated with cellular stress
12/12/2002	WO2002098392A1 Nsaid formulation comprising a granular composition and an extra-granular composition
12/12/2002	WO2002098363A2 NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM
12/12/2002	WO2002098360A2 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease
12/12/2002	WO2002098222A1 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds
12/12/2002	WO2002089850A8 Long acting antimicrobic preparation
12/12/2002	WO2002087600A8 Use of phyllanthus constituents for treating or preventing infections caused by hepatit
12/12/2002	WO2002083879A3 Immunotherapy based on dendritic cells
12/12/2002	WO2002076982A3 Non-nucleoside reverse transcriptase inhibitors
12/12/2002	WO2002076494A3 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
12/12/2002	WO2002072015A3 M cell directed vaccines
12/12/2002	WO2002068015A9 Modular infusion device and method
12/12/2002	WO2002067984A3 Materials and methods for detecting, preventing, and treating hiv and fiv retroviral infection
12/12/2002	WO2002066458A3 2-thio-substituted imidazole derivatives and the use thereof in the pharmaceutical industry
12/12/2002	WO2002065989A3 Aminoglycoside treatment for lysosomal storage diseases
12/12/2002	WO2002064552A8 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES
12/12/2002	WO2002064161A3 Method and compositions for immunization with the pseudomonas v antigen
12/12/2002	WO2002064089A3 Methods of preventing ventilator associated pneumonia by oral administration of antimicrobial ib-367 peptides
12/12/2002	WO2002050106A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4
12/12/2002	WO2002045742A3 Lipoteichoic acid immunogenic compositions and methods of making and using thereof
12/12/2002	WO2002044718A3 S.aureus protein staau r2, gene encoding it and uses thereof
12/12/2002	WO2002030983A3 Plasma fraction containing bikunin, method for the production thereof and use of the same
12/12/2002	WO2002018593A3 Modulation of fas and fasl expression
12/12/2002	WO2002008292A3 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
12/12/2002	WO2002004424A9 Pyrazole derivatives
12/12/2002	WO2002004017A3 Method for preparing oral vaccines
12/12/2002	WO2001038360A9 Novel hcv non-structural polypeptide
12/12/2002	WO2000032152A3 Compositions and methods for regulating bacterial pathogenesis
12/12/2002	US20020188122 Such as pyridine-4-carboxaldehyde-(4-Morpholinylprop-3-yl) imine for use in therapy as cytokine inhibitors
12/12/2002	US20020188107 Plant protein for use in the treatment of cancer
12/12/2002	US20020188102 Peptide for use as microbiocides
12/12/2002	US20020188100 Boron compound for use in the treatment of stroke, heart defects, inflammation, autoimmune and cancer disease
12/12/2002	US20020188016 Heterocycle derivatives and methods of use
12/12/2002	US20020188009 Bisarylimidazolyl fatty acid amide hydrolase inhibitors
12/12/2002	US20020187999 Anti-inflammatory uses of manzamines
12/12/2002	US20020187976 New benzofurane derivatives, their preparation process, their use as medicaments and the pharmaceutical compositions containing them
12/12/2002	US20020187946 Mammalian iap gene family, primers, probes and detection methods
12/12/2002	US20020187936 Methods of treating liver disease and liver damage with growth hormone and foxM1B
12/12/2002	US20020187930 Substances and their uses
12/12/2002	US20020187523 Extracellular signaling molecules
12/12/2002	US20020187473 Polyamide nucleic acid derivatives, and agents and processes for preparing them
12/12/2002	US20020187197 Templating of solid particles by polymer multilayers
12/12/2002	US20020187163 Herpes simplex virus comprising a mutation within the BstEII-EcoNI fragment of the BamHI x fragment of said virus; cancer vaccine
12/12/2002	US20020187161 H. pylori antigens
12/12/2002	US20020187160 Vaccine delivery system
12/12/2002	US20020187155 Ringworm vaccine
12/12/2002	US20020187152 Administering a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells; vaccines, diagnosis, screening
12/12/2002	US20020187143 Methods and compositions for reducing immune response
12/12/2002	US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002	US20020187068 Method of inactivating pathogens
12/12/2002	CA2830887A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002	CA2457959A1 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
12/12/2002	CA2449843A1 Non-peptide gnrh agents, pharmaceutical compositions and methods for their use, and processes for preparing them
12/12/2002	CA2449770A1 Novel anti-infectives
12/12/2002	CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002	CA2449132A1 Recombinant antibodies against infectious bursal disease virus (ibdv)
12/12/2002	CA2449109A1 2-heteroaryl-imidazotriazinones and their use in the treatment of inflammatory or immune diseases
12/12/2002	CA2449097A1 5-ethyl-imidazotriazinones
12/12/2002	CA2448606A1 Nucleic acid-associated proteins
12/12/2002	CA2448444A1 Molecular clones with mutated hiv gag/pol, siv gag and siv env genes
12/12/2002	CA2448040A1 Antimycotic agent
12/12/2002	CA2447935A1 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
12/12/2002	CA2447111A1 Solutions of alkoxylated alkanol amide surfactants and antimicrobial compounds
12/12/2002	CA2430697A1 Atp-binding cassette transporter-like molecules and uses thereof
12/11/2002	WO2002000231A1 Use of a formulation made of or containing at least one dissimilated milk serum
12/11/2002	EP1264840A1 Long lasting fusion peptide inhibitors of viral infection
12/11/2002	EP1264827A1 Process for the preparation of Tosylbenzylformamides
12/11/2002	EP1264612A1 Method for nasal application of a medicinal substance
12/11/2002	EP1264597A2 Methods and compositions for treating cancer
12/11/2002	EP1263982A1 Phosphatidyl serine receptors and uses thereof
12/11/2002	EP1263965A2 Avirulent, immunogenic flavivirus chimeras
12/11/2002	EP1263960A2 Anti-tissue factor antibodies with enhanced anticoagulant potency
12/11/2002	EP1263959A1 Antibodies to human cd154
12/11/2002	EP1263943A1 Protein c derivatives
12/11/2002	EP1263940A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies
12/11/2002	EP1263936A1 Altered strain of the modified vaccinia virus ankara (mva)
12/11/2002	EP1263791A2 Human g-protein chemokine receptor (ccr5) hdgnr10
12/11/2002	EP1263789A2 Antibody inhibiting the binding between gp120 and dc-sign and screening methods
12/11/2002	EP1263786A2 Methods and compositions for immunoregulation
12/11/2002	EP1263781A1 Viral antigen and vaccine against isav (infectious salmon anaemia virus)
12/11/2002	EP1263775A1 Hla binding peptides and their uses

1 ... 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 ... 1798